uniQure (NASDAQ:QURE) Rating Increased to Hold at Wall Street Zen

uniQure (NASDAQ:QURE) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities research analysts have also commented on the stock. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. TD Cowen reissued a “buy” rating on shares of uniQure in a report on Tuesday, March 3rd. Barclays reduced their price objective on uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a report on Monday, March 23rd. Wells Fargo & Company raised uniQure from an “equal weight” rating to an “overweight” rating and lifted their target price for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $14.00 target price on uniQure in a research report on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $42.75.

uniQure Price Performance

NASDAQ:QURE opened at $14.77 on Friday. The firm has a market cap of $923.57 million, a PE ratio of -4.28 and a beta of 0.73. The company’s 50-day moving average price is $19.91 and its two-hundred day moving average price is $29.40. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. uniQure has a 12 month low of $7.76 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analysts’ expectations of $4.84 million. On average, equities analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other uniQure news, CEO Matthew C. Kapusta sold 14,581 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the transaction, the chief executive officer owned 660,658 shares in the company, valued at approximately $5,985,561.48. This trade represents a 2.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director owned 20,439 shares of the company’s stock, valued at $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,399 shares of company stock valued at $1,527,645 in the last ninety days. 4.79% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

Several large investors have recently bought and sold shares of the company. Private Trust Co. NA bought a new position in shares of uniQure during the third quarter worth $28,000. Torren Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at $28,000. Jones Financial Companies Lllp raised its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc acquired a new stake in uniQure during the 4th quarter worth $48,000. Finally, Smartleaf Asset Management LLC bought a new position in uniQure during the fourth quarter worth about $48,000. Institutional investors own 78.83% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.